MapLight Therapeutics, Inc. (MPLT) Stock Score, Valuation & Financial Research

MapLight Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for MPLT

MapLight Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 7.88. These figures are a research snapshot, not a buy or sell recommendation.

What MapLight Therapeutics, Inc. does

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

MapLight Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. The company focuses on the discovery and development of novel therapeutics for central nervous system disorders by identifying and modulating specific neural circuits, and it currently funds its operations primarily through equity financing and capital raises.

Products and services

  • The company is developing a pipeline of product candidates targeting CNS disorders, including ML-007 for the treatment of schizophrenia and agitation associated with dementia (ADP), which utilizes a muscarinic receptor-based approach.

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

MPLT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 7.88
Market capitalization:
334.19M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -229.83M
Free cash flow:
USD -138.61M
Cash:
USD 71.63M
Total debt:
USD 1.99M
EPS:
USD -5.18

What stands out

  • Free cash flow is USD -138.61M, negative for the stored period.
  • The balance sheet shows USD 71.63M of cash versus USD 1.99M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 69.65M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for MPLT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can MPLT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is MPLT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for MPLT to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of MPLT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-05.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research MPLT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.